Current Partner Studies

Lupus Therapeutics has been involved in some of the most important breakthroughs in lupus research. And today, we’re helping to guide what we hope will be future breakthroughs.

Ongoing

Study Name: AbbVie SELECT-SLE

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Up to 20 LuCIN sites (U.S. & CAN)

Study Status: Actively Recruiting

Study Name: BIOGEN AMETHYST

A Study to Assess the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

18 LuCIN sites (U.S. and Canada)

Study Status: Actively Recruiting

Study Name: BIOGEN TOPAZ

A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care (TOPAZ-1)

21 LuCIN sites (U.S. and Canada)

Study Status: Actively Recruiting

Study Name: BMS-POETYK SLE 1

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

15 LuCIN sites (U.S. and Canada)

Study Status: Actively Recruiting

Study Name: BMS-POETYK SLE 2

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

12 LuCIN sites (U.S.)

Study Status: Actively Recruiting

Study Name: Gilead COSMIC

Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)

Up to 10 LuCIN sites (U.S.)

Study Status: Actively Recruiting

Study Name: Lilly BT01

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

4 LuCIN sites (U.S. and Canada)

Study Status: Actively Recruiting

Study Name: SIRIUS-LN

Study of safety, efficacy and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus nephritis

Up to 15 LuCIN sites (U.S. & CAN)

Study Status: Actively Recruiting

Study Name: SIRIUS-SLE 1

Phase 3 study to evaluate two regimens of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1)

Up to 20 LuCIN sites (U.S. & CAN)

Study Status: Actively Recruiting

Study Name: SIRIUS-SLE 2

Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)

Up to 20 LuCIN sites (U.S. & CAN)

Study Status: Actively Recruiting

Study Name: UCB

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)

25 LuCIN sites (U.S. and Canada)

Study Status: Closed for Recruitment

Study Name: VeraTx COMPASS

Atacicept in Subjects with Active Lupus Nephritis (COMPASS)

14 LuCIN sites (U.S. and Canada)

Study Status: Paused

Past

Study Name: AKER-ORKIDS

Omega-3 Replacement With Krill Oil in Disease Management of SLE (ORKIDS)

22 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: AMG570

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

16 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: AMG592

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

10 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: BMS-PAISLEY SLE

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

21 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: CELGENE-CC-220

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

23 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: DIVINE

Dynamic Imaging of Variation in Lupus Nephritis (DIVINE)

7 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: JANSSEN ORCHID

A Study of Guselkumab in Participants With Active Lupus Nephritis (ORCHID-LN)

5 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: Lilly-KFAJ

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) (ISLAND-SLE)

13 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: RIFLE-PREDNISONE

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (RIFLE)

21 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: TAKEDA-TAK-079

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

10 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: VALUE-App

Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus (VALUE)

10 LuCIN sites (U.S. and Canada)

Study Status: Completed

Study Name: VIB7734

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE (RECAST SLE)

7 LuCIN sites (U.S. and Canada)

Study Status: Completed